Loading
A 5 mg tamoxifen dose halves breast cancer recurrence after precancer with far fewer side effects than the full dose. Almost nobody is prescribed it. Change who can prescribe.
TAM-01 showed 5 mg a day reduced recurrence after DCIS, atypical hyperplasia or LCIS by about half with side effects close to placebo, yet uptake of risk-reducing medication is under 10%. Propose nurse and pharmacist prescribing, an automatic offer at diagnosis of high-risk lesions, and inclusion in screening-risk feedback.
One bottleneck page and 27 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
For women at raised risk, a 5-year course of tamoxifen offers long-lasting protection against the commonest kind of breast cancer. Uptake is low because of side effects and fear of rare serious harms; low-dose tamoxifen (TAM-01) is now being tested to improve the balance. It has not been shown to save lives.
Shares IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years, Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Estrogen receptor (ERα), Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.